Vitravene Preservative Free is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 15, 2012. Details of Vitravene Preservative Free's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5442049 | Oligonucleotides for modulating the effects of cytomegalovirus infections |
Aug, 2012
(12 years ago) |
Expired
|
| US5595978 | Composition and method for treatment of CMV retinites |
Aug, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Vitravene Preservative Free is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vitravene Preservative Free's family patents as well as insights into ongoing legal events on those patents.
Vitravene Preservative Free's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vitravene Preservative Free's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 15, 2012 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vitravene Preservative Free Generics:
There are no approved generic versions for Vitravene Preservative Free as of now.
About Vitravene Preservative Free
Vitravene Preservative Free is a drug owned by Novartis Pharmaceuticals Corp. It is used for treating CMV retinitis through intravitreal administration of a phosphorothioate oligonucleotide targeting CMV mRNA. Vitravene Preservative Free uses Fomivirsen Sodium as an active ingredient. Vitravene Preservative Free was launched by Novartis in 1998.
Approval Date:
Vitravene Preservative Free was approved by FDA for market use on 26 August, 1998.
Active Ingredient:
Vitravene Preservative Free uses Fomivirsen Sodium as the active ingredient. Check out other Drugs and Companies using Fomivirsen Sodium ingredient
Treatment:
Vitravene Preservative Free is used for treating CMV retinitis through intravitreal administration of a phosphorothioate oligonucleotide targeting CMV mRNA.
Dosage:
Vitravene Preservative Free is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 6.6MG/ML | INJECTABLE | Discontinued | INJECTION |